GLPGF - Galapagos Nv

NYSE * Healthcare * Biotechnology

$33.27

+$0.00 (+0.00%)

About Galapagos Nv

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

GLPGF Key Statistics

Market Cap

$3.21B

P/E Ratio

8.56

P/B Ratio

0.58

EPS

$5.69

Revenue Growth

+10.9%

Profit Margin

0.3%

Employees

704

How GLPGF Compares to Peers

GLPGF has the lowest P/E ratio in Biotechnology, suggesting it may be the most undervalued
GLPGF has the fastest revenue growth among competitors
GLPGF is the smallest among peers, which may offer higher growth potential

P/E Rank

#1

of 6

Margin Rank

#4

of 6

Growth Rank

#1

of 6

Size Rank

#6

of 6

CompanyP/EGrowthCompare
GLPGF8.611%-
AMGN24.90%vs AMGN
GILD20.30%vs GILD
VRTX28.80%vs VRTX
REGN18.10%vs REGN
BIIB20.9-0%vs BIIB

Galapagos Nv Company Information

Headquarters
Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800, undefined
Website
www.glpg.com
Sector
Healthcare
Industry
Biotechnology
Data Updated:
Ready to invest in GLPGF?

Commission-free trading available. Affiliate links.

Upcoming Events for GLPGF